Home Newsfeeds Dawson James Downgrades Crown ElectroKinetics to Neutral

Dawson James Downgrades Crown ElectroKinetics to Neutral

Dawson James analyst James McIlree downgrades Crown ElectroKinetics (NASDAQ:CRKN) from Buy to Neutral.

byBenzinga Newsdesk

September 20, 2022

1 minute read

Dawson James analyst James McIlree downgrades Crown ElectroKinetics (NASDAQ:CRKN) from Buy to Neutral.

AbbVie Is ‘Successfully Positioned To Absorb Humira Biosimilar Erosion’: Analyst

By Vandana Singh

May 17, 1:47 PM

Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humira biosimilar erosion, drive growth with Skyrizi, Rinvoq, and emraclidine, and achieve a high single-digit CAGR from 2024 to 2029.

ABBV

Wall Street’s Most Accurate Analysts’ Views On 3 Materials Stocks Delivering High-Dividend Yields

By Avi Kapoor

April 16, 7:48 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.